AVI BioPharma said this week that it has appointed K. Michael Forrest to its board of directors. Forrest, who is filling the unexpired term of former director Raymond Ruddon, will serve until 2006. Rudden is transitioning to the company’s scientific advisory board.
Forrest was previously CEO of Cellegy Pharmaceuticals. Prior to this, he served in various positions at American Cyanimid and Pfizer.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
